A research team led by Zhou Haibo at the Chinese Academy of Sciences has created a new high‑throughput platform called iGOF‑Perturb‑seq that can test the effects of turning on thousands of genes inside living animals. By focusing on about 1,000 transcription factors – the proteins that switch genes on or off – the scientists mapped how each one changes the behavior of astrocytes, the star‑shaped cells that support and protect neurons. Their work produced a detailed “functional atlas” of astrocyte regulators, revealing many previously unknown genes that can push these cells toward a harmful, disease‑driving state. Using this atlas, the team identified several promising gene targets and demonstrated that manipulating them dramatically improved outcomes in mouse models of Alzheimer’s disease, offering a fresh strategy that goes beyond the traditional focus on amyloid plaques. Because the platform works in living tissue, it overcomes the limitations of earlier lab‑dish methods that could only turn genes off and could not capture the brain’s complex environment. The researchers plan to make the massive data set publicly available, giving scientists worldwide a new toolbox to discover precise targets for Alzheimer’s, Parkinson’s, ALS, stroke, depression and other brain disorders. This could accelerate the development of innovative, more effective therapies by solving the long‑standing “target shortage” problem in brain‑disease drug research.
Read moreCell‑based gene therapies (CGT) are being hailed as the next breakthrough in cancer treatment, but they come with a steep learning curve. Unlike traditional pills or antibody drugs, CGTs require far more detailed trial designs, larger data packages and deeper safety checks. Experts say the paperwork for a CGT study can be up to 50 % larger than for a conventional drug, because regulators need to see solid proof that the therapy’s permanent DNA edits won’t cause unexpected problems down the line. At the same time, China is emerging as a powerhouse for this kind of innovation. What used to be a market for selling foreign drugs is now a key hub for global research. Multinational companies are weaving Chinese sites into multi‑regional trials, tapping the country’s fast‑moving discovery labs and massive patient pools. According to industry leaders, drug discovery in China can be two to three times quicker than abroad while slashing costs by 60‑70 %. Once a candidate reaches the clinical stage, patient recruitment can be five times faster and development expenses cut in half. This "Create with China" strategy is turning the nation into a critical link in the worldwide fight against cancer, accelerating the arrival of cutting‑edge gene therapies for patients around the globe.
Read moreProfessor Li Jin, president of Shanghai Gaobo Cancer Hospital, explains how a new “four‑in‑one” research platform could shrink the time it takes to bring cancer medicines to patients. Traditional drug discovery relies on a long chain of animal tests—cells, mice, rabbits, dogs, even primates—making the process slow, costly and ethically fraught. Emerging technologies such as organoids and micro‑physiological systems now allow scientists to grow miniature, human‑like organs (heart, liver, kidney, skin, muscle, nerve and tumor) on a single chip. These “body‑on‑a‑chip” devices mimic real human biology, letting researchers test drug toxicity and anti‑tumor activity all at once and predict the safest and most effective doses before a human trial begins. With accurate quantitative pharmacology models, early‑stage trials could be designed with just a handful of patients instead of dozens, slashing Phase I timelines from years to months. Li argues that regulators must rethink the need for huge, lengthy trials and consider conditional approvals based on solid mechanistic data. The ultimate goal is to give newly diagnosed cancer patients targeted therapy right away, rather than watching them lose precious time waiting for approvals. At Shanghai Gaobo, Li and his team are building an integrated innovation platform that applies these ideas, aiming to turn a decade‑long development cycle into a two‑year reality while upholding patient safety and ethical standards.
Read more